Pentacyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos Patents (Class 546/42)
  • Patent number: 10668064
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, Y1, Y2, or L are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: June 2, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Mingzhe Ji, Scott E. Lazerwith, Hyung-Jung Pyun
  • Patent number: 9708310
    Abstract: A phenanthroindolizidine and phenanthroquinolizidine alkaloid having a hydroxyl group on the phenanthrene ring thereof was synthesized, which exhibits potent activity as an anticancer agent against, such as breast cancer, lung cancer, and prostate cancer.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: July 18, 2017
    Assignee: CHINA MEDICAL UNIVERSITY
    Inventors: Ta-Hsien Chuang, Chien-Fu Li, Chia-Chen Tsai, Chi-Fen Chang, Chieh-Yu Peng
  • Patent number: 9700554
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, Y1, Y2, or L are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: July 11, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Mingzhe Ji, Scott E. Lazerwith, Hyung-jung Pyun
  • Patent number: 9421214
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, Y1, Y2, or L are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: August 23, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Mingzhe Ji, Scott E. Lazerwith, Hyung-Jung Pyun
  • Patent number: 9139582
    Abstract: The present invention relates to electronic devices, in particular organic electroluminescent devices, comprising compounds of the formula (1), and the corresponding compounds.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: September 22, 2015
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Christof Pflumm, Philipp Stoessel, Arne Buesing, Dominik Joosten
  • Patent number: 8986855
    Abstract: Derivatives of benzo[h]naphtho[1,2-f]quinoline and organic light emitting devices (OLEDs) including them are disclosed. The subject compounds impart high efficiency, low driving voltage, high luminance and long lifespan to the OLEDs. The subject compounds may be used as light emitting materials, as electron transporting materials, or as electron injecting materials. Because the subject compounds have high glass transition temperatures or high melting points, OLEDs including them exhibit high durability in storage or operation. Suitable substituents may be selected from deuterium, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, aryloxy, arylthio, aryl, aryl- or heteroaryl-substituted amino, heteroaryl, condensed polycyclic, halogen, cyano, nitro, hydroxyl and carboxyl groups.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: March 24, 2015
    Assignee: Samsung Display Co., Ltd.
    Inventors: Jin-O Lim, Seok-Hwan Hwang, Young-Kook Kim, Hye-Jin Jung, Sang-Hyun Han, Bo-Ra Lee, Jong-Hyuk Lee
  • Patent number: 8957084
    Abstract: The application is directed to compounds of Formula I-A and pharmaceutically acceptable salts and solvates thereof, wherein Cy, R1a-R3a, R4a, and R4b are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: February 17, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Donald J. Kyle, Laykea Tafesse, Xiaoming Zhou
  • Patent number: 8951649
    Abstract: Derivatives of benzo[h]naphtho[1,2-f]quinoline and organic light emitting devices (OLEDs) including them are disclosed. The subject compounds impart high efficiency, low driving voltage, high luminance and long lifespan to the OLEDs. The subject compounds may be used as light emitting materials, as electron transporting materials, or as electron injecting materials. Because the subject compounds have high glass transition temperatures or high melting points, OLEDs including them exhibit high durability in storage or operation. Suitable substituents may be selected from deuterium, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, aryloxy, arylthio, aryl, aryl- or heteroaryl-substituted amino, heteroaryl, condensed polycyclic, halogen, cyano, nitro, hydroxyl and carboxyl groups.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: February 10, 2015
    Assignee: Samsung Display Co., Ltd.
    Inventors: Jin-O Lim, Seok-Hwan Hwang, Young-Kook Kim, Hye-Jin Jung, Sang-Hyun Han, Bo-Ra Lee, Jong-Hyuk Lee
  • Publication number: 20140374733
    Abstract: An object of the present invention is to provide a photoelectric conversion element having a photoelectric conversion film which exhibits heat resistance, a high photoelectric conversion efficiency, a low level of dark currents, rapid response, and sensitivity characteristics to red and can be produced by a vapor deposition processing that is continuously performed under a high-temperature condition. The photoelectric conversion element of the present invention is a photoelectric conversion element in which a conductive film, a photoelectric conversion film containing a photoelectric conversion material, and a transparent conductive film are laminated on one another in this order, wherein the photoelectric conversion material includes a compound represented by Formula (1).
    Type: Application
    Filed: September 5, 2014
    Publication date: December 25, 2014
    Applicant: FUJIFILM Corporation
    Inventors: Yuki HIRAI, Yosuke YAMAMOTO, Tomoaki YOSHIOKA, Eiji FUKUZAKI, Katsuyuki YOFU, Masaaki TSUKASE, Mitsumasa HAMANO, Takahiko ICHIKI
  • Patent number: 8901298
    Abstract: The present invention relates to condensed aromatic compounds with multiple ring bridging of the general formulae (1), (2), (3), (4) and (5). The invention furthermore relates to the use of the compounds according to the invention in an organic electronic device and to a process for the preparation of the compounds according to the invention. The invention furthermore relates to an electronic device which comprises the compounds according to the invention.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: December 2, 2014
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Christof Pflumm, Holger Heil, Arne Buesing
  • Publication number: 20140306186
    Abstract: In an aspect, an organic compound and an organic light-emitting diode (OLED) including the same are provided.
    Type: Application
    Filed: July 22, 2013
    Publication date: October 16, 2014
    Inventors: Seul-Ong Kim, Dong-Woo Shin, O-Hyun Kwon, Kyul Han
  • Publication number: 20140200350
    Abstract: There are provided compounds comprising optionally substituted (FORMULA I) fused with one or two optionally substituted (FORMULA II), wherein A and E each independently represent —CH2—, —NH—, —O—, —S—, or —C(?O)— and B represents a bond, —CH2—, —NH—, —O—, —S—, or —C(?O)—, said compound having directly or indirectly attached thereto at least one acyl and/or oxime ester group. Such compounds are useful inter alias as photoinitiators.
    Type: Application
    Filed: May 24, 2012
    Publication date: July 17, 2014
    Applicant: AMERICAN DYE SOURCE, INC.
    Inventors: My T. Nguyen, Jean-Philippe Tremblay-Morin, Philippe Gaudreault
  • Patent number: 8741917
    Abstract: The present invention provides compounds of formula I: formula (I) wherein X1-X4 and R1-R12 have any of the values defined in the specification, as well as salts and prodrugs thereof, which inhibit major molecular mechanisms associated with bacterial cell division and proliferation so as to be useful for the treatment and/or prevention of bacterial infections. The invention also provides compositions comprising these compounds as well as methods for using these compounds to inhibit bacterial cell division and proliferation and to treat bacterial infections.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: June 3, 2014
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Edmond J. LaVoie, Ajit Parhi, Daniel S. Pilch, Malvika Kaul
  • Publication number: 20140134280
    Abstract: An extract of Cynanchum sp. in use of arthritis treatment is provided. The extract of Cynanchum sp. and an active ingredient contained therein, antofine, are applicable to a method, pharmaceutical composition and dietary supplement for treatment of arthritis. A mass production of antofine from plant extracts is also provided.
    Type: Application
    Filed: April 27, 2012
    Publication date: May 15, 2014
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jennline Sheu, Lain-Tze Lee, Ying-Chu Shih, Cheng-Yu Lee, Yi-Ching Lee, Jir-Mehng Lo, Tien-Soung Tong, Jui-Hung Yen, Kuo-Kuei Huang, Ying-Fei Tsai
  • Patent number: 8618123
    Abstract: Disclosed are novel gamma secretase inhibitors of the formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, wherein L1, n, X, Ar, Y, Z, Q, and Q1 are as defined herein. Also disclosed are methods for inhibiting gamma secretase, methods for treating Alzheimer's disease, methods of treating one or more neurodegenerative diseases, and methods of inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain) using the compounds of formula 1.0.
    Type: Grant
    Filed: July 15, 2008
    Date of Patent: December 31, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Thavalakulamgara K. Sasikumar, Duane A. Burnett, Theodros Asberom, Wen-Lian Wu, Hongmei Li, Ruo Xu, Hubert B. Josien
  • Publication number: 20130320262
    Abstract: The present invention relates to a compound of a formula (I), (II) or (III), to the use of this compound in an electronic device, and to an electronic device comprising one or more compounds of the formula (I), (II) or (III). The invention furthermore relates to a process for the preparation of a compound of the formula (I), (II) or (III) and to a formulation comprising one or more compounds of the formula (I), (II) or (III).
    Type: Application
    Filed: January 18, 2012
    Publication date: December 5, 2013
    Applicant: MERCK PATENT GMBH
    Inventors: Irina Martynova, Amir Hossain Parham, Christof Pflumm
  • Patent number: 8598148
    Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: December 3, 2013
    Assignee: President and Fellows of Harvard College
    Inventors: Andrew G. Myers, Mark G. Charest, Christian D. Lerner, Jason D. Brubaker, Dionicio R. Siegel
  • Patent number: 8569327
    Abstract: A novel compound having an excellent NF?B inhibitory effect is provided. Specifically disclosed is a compound represented by the following formula (1) or a salt thereof: wherein, R1 represents a hydrogen atom, a lower alkyl group, or the like; R2 represents a hydrogen atom, a lower alkyl group, a halogen atom, or the like; R3 represents a hydrogen atom, a lower alkyl group, a hydroxyl group, or a halogen atom; R4 represents a hydrogen atom or a lower alkyloxy group; R5 represents a hydrogen atom, a lower alkyloxy group, a halogen atom, a hydroxyl group, or a methylenedioxy group formed together with R6 or an isopropylidenedioxy group formed together with R6; R6 represents a hydrogen atom, a lower alkyloxy group, or a methylenedioxy group formed together with R5 or an isopropylidenedioxy group formed together with R5; R7 represents a hydrogen atom or a lower alkyl group; and R8 represents a hydrogen atom, a hydroxyl group, an amino group, a lower alkylcarbonyloxy group, or a halogen atom.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: October 29, 2013
    Assignee: Kabushiki Kaisha Yakult Honsha
    Inventors: Takashi Ikeda, Seigo Sawada, Takashi Yaegashi, Takeshi Matsuzaki, Shusuke Hashimoto, Ryuta Yamazaki
  • Publication number: 20130274473
    Abstract: The current invention relates to novel platinum(II) based organometallic materials. These materials show high emission quantum efficiencies and low self-quenching constant. Also provided are high efficiency, green to orange emitting organic light-emitting diode (OLED) that are fabricated using platinum(II) based organometallic materials as the light-emitting material. The organometallic materials of the invention are soluble in common solvents; therefore, solution process methods such as spin coating and printing can be used for device fabrication. The devices fabricated from these materials show low efficiency roll-off.
    Type: Application
    Filed: April 11, 2013
    Publication date: October 17, 2013
    Applicant: The University of Hong Kong
    Inventors: Chi Ming CHE, Chi Fai KUI, Chi Chung KWOK
  • Publication number: 20130181202
    Abstract: There is provided a compound represented by a specific formula, which has an absorption maximum at 400 nm or more and less than 720 nm in a UV-visible absorption spectrum, wherein a molar extinction coefficient is 10,000 mol?1·l·cm?1 or more at the absorption maximum wavelength, and a difference between a melting point and a deposition temperature (a melting point?a deposition temperature) is 31° C. or more.
    Type: Application
    Filed: March 7, 2013
    Publication date: July 18, 2013
    Applicant: FUJIFILM CORPORATION
    Inventor: FUJIFILM CORPORATION
  • Publication number: 20130131006
    Abstract: The present invention relates to a method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of AGE-albumin in cells of the mononuclear phagocyte system, to an AGE-albumin synthesis inhibitor, and to a pharmaceutical composition comprising the AGE-albumin synthesis inhibitor for preventing or treating degenerative disease and autoimmune disease. The AGE-albumin of the present invention is synthesized and secreted in human microglia or human macrophages in an Alzheimer's model, stroke model, Parkinson's disease model and rheumatoid arthritis model. The AGE-albumin synthesis and secretion are caused by oxidative stress. The expression of RAGE increases in first-order human neurons or cartilage cells to which AGE-albumin is administered, whereupon a MAPK signaling pathway is activated and the expression of Bax increases to induce an increase in calcium in mitochondria, thus finally inducing cell death.
    Type: Application
    Filed: April 28, 2011
    Publication date: May 23, 2013
    Applicant: Gachon University of Industry-Academic Cooperation Foundation
    Inventors: Bong Hee Lee, Kyung Hee Byun
  • Patent number: 8440649
    Abstract: Treatment of coronavirus infection with phenanthroindolizidine analogues.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: May 14, 2013
    Assignee: National Health Research Institutes
    Inventors: Shiow-Ju Lee, Cheng-Wei Yang, Yue-Zhi Lee
  • Publication number: 20130026422
    Abstract: The present invention relates to a compound according to formula (I), to the use thereof in an electronic device and to an electronic device which comprises one or more compounds according to formula (I).
    Type: Application
    Filed: March 16, 2011
    Publication date: January 31, 2013
    Applicant: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Christof Pflumm
  • Patent number: 8362028
    Abstract: Pseudobase benzo[c]phenanthridines and the pharmaceutically acceptable salts thereof of Formula I are provided herein. The variables R, R1, R2, R3, and R4 are defined herein. Certain pseudobase benzo[c]phenanthridines provided herein act as prodrugs, targeting the parent benzo[c]phenanthridinium alkaloid to hydrophilic or hydrophobic regions in the body. Pharmaceutical compositions comprising a pseudobase benzo[c]phenanthridine and a carrier, excipient, or diluent are provided herein. Methods of treating or preventing microbial, fungal and or viral infections and methods of treating diseases and disorders responsive to protein kinase C modulation, topoisomerase I, and/or topoisomerase II modulation are also provided.
    Type: Grant
    Filed: April 6, 2009
    Date of Patent: January 29, 2013
    Assignee: Yale University
    Inventors: Kenneth Shaw, Mingbao Zhang, Amy F. T. Arnsten
  • Publication number: 20130001529
    Abstract: A heterocyclic compound represented by Formula 1 below and an organic light-emitting device including the heterocyclic compound: wherein R1 to R13 are defined as in the specification.
    Type: Application
    Filed: February 15, 2012
    Publication date: January 3, 2013
    Applicant: SAMSUNG MOBILE DISPLAY CO., LTD.
    Inventors: Jin-O Lim, Seok-Hwan Hwang, Young-Kook Kim, Hye-Jin Jung, Sang-Hyun Han, Bo-Ra Lee, Jong-Hyuk Lee
  • Publication number: 20120292576
    Abstract: The present invention relates to compounds of the formula (I) and to the use thereof in organic electronic devices, and to organic electronic devices which comprise compounds of the formula (I), preferably as hole-transport materials and/or as matrix materials, in particular in combination with a further matrix material.
    Type: Application
    Filed: December 17, 2010
    Publication date: November 22, 2012
    Applicant: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Christof Pflumm, Constanze Brocke
  • Publication number: 20120283220
    Abstract: The present invention provides compounds of Formula (I-IV): compositions containing the same, and methods of use thereof such as for the treatment of cancer.
    Type: Application
    Filed: September 22, 2010
    Publication date: November 8, 2012
    Inventors: Kuo-Hsiung Lee, Xiaoming Yang, Qian Shi, Kenneth F. Bastow, Che-Ming Teng, Tse-Ming Hong, Pan-Chyr Yang, Shuenn-Chen Yang
  • Publication number: 20120217492
    Abstract: Disclosed are an organic compound, an organic electronic device using the same, and a terminal thereof.
    Type: Application
    Filed: October 29, 2010
    Publication date: August 30, 2012
    Applicant: DUKSAN HIGH METAL CO., LTD.
    Inventors: Dongha Kim, Soungyun Mun, Jungcheol Park, Jinuk Ju, Jangyeol Baek, Wonsam Kim, Eunkyung Kim, Daehyuk Choi, Junghwan Park
  • Publication number: 20120202997
    Abstract: The present invention relates to compounds of the formula (1) and formula (2) which are suitable for use in electronic devices, in particular organic electroluminescent devices.
    Type: Application
    Filed: September 9, 2010
    Publication date: August 9, 2012
    Applicant: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Christof Pflumm
  • Publication number: 20120190703
    Abstract: The present invention relates to the salts of (+)-13a-(S)-deoxytylophorinine represented by the general formula (I), the preparation method thereof, the pharmaceutical compositions containing them, and their use as medicaments for prevention and/or treatment of cancer and/or inflammation disease.
    Type: Application
    Filed: July 9, 2010
    Publication date: July 26, 2012
    Applicant: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Shishan Yu, Xiaoguang Chen, Haining Lv, Yan Li, Song Xu, Shuanggang Ma, Zhenjia Liu, Yi Zhang, Jinping Hu
  • Publication number: 20120012824
    Abstract: Disclosed is a metal complex compound represented by the following Chemical Formula 1, and an organic light emitting diode device including the same. In Chemical Formula 1, M, R1 to R8, A1 to A6, and y are the same as defined in the detailed description.
    Type: Application
    Filed: June 24, 2011
    Publication date: January 19, 2012
    Applicant: Samsung Mobile Display Co., Ltd.
    Inventors: Hamada Yuji, Kwan-Hee Lee
  • Patent number: 8072137
    Abstract: To provide a material for an organic light emitting device showing a light emission hue with an extremely good purity and outputting light having high luminance and a long lifetime with high efficiency, the present invention relates to a fused heterocyclic compound having at least one partial structure represented by the following general formula [1].
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: December 6, 2011
    Assignee: Canon Kabushiki Kaisha
    Inventors: Hiroki Ohrui, Shinjiro Okada, Akihiro Senoo, Naoki Yamada, Masanori Muratsubaki
  • Patent number: 8071227
    Abstract: Disclosed are new compounds and an organic light emitting diode using the same. The organic light emitting diode using the new compound according to the present invention exhibits excellent characteristics in terms of actuating voltage, light efficiency, and lifespan.
    Type: Grant
    Filed: December 3, 2007
    Date of Patent: December 6, 2011
    Assignee: LG Chem, Ltd.
    Inventors: Byung-Sun Jeon, Wook-Dong Cho, Jeung-Gon Kim, Sang-Young Jeon, Yeon-Hwan Kim
  • Publication number: 20110201638
    Abstract: A novel compound having an excellent NF?B inhibitory effect is provided and specifically disclosed is a compound represented by the following formula (1) or a salt thereof: wherein, R1 represents a hydrogen atom, a lower alkyl group, a lower alkyloxy group, or a halogen atom; R2 represents a hydroxyl group, or a lower alkyloxy group; R3 represents a hydrogen atom, a lower alkyl group, or a halogen atom; R4 represents a hydrogen atom or a lower alkyloxy group; R5 represents a hydrogen atom, a lower alkyloxy group, a halogen atom, a hydroxyl group, or a methylenedioxy group formed together with R6 or an isopropylidenedioxy group formed together with R6; R6 represents a hydrogen atom, a lower alkyloxy group, or a methylenedioxy group formed together with R5 or an isopropylidenedioxy group formed together with R5; R7 represents a hydrogen atom or a lower alkyl group; and R8 represents a hydrogen atom, a hydroxyl group, an amino group, or a lower alkylcarbonyloxy group (excluding the case where R1, R3, R4 and R7
    Type: Application
    Filed: October 23, 2009
    Publication date: August 18, 2011
    Applicant: KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Takashi Ikeda, Seigo Sawada, Takashi Yaegashi, Takeshi Matsuzaki, Shusuke Hashimoto, Ryuta Yamazaki
  • Publication number: 20110201637
    Abstract: A novel compound having an excellent NF?B inhibitory effect is provided. Specifically disclosed is a compound represented by the following formula (1) or a salt thereof: wherein, R1 represents a hydrogen atom, a lower alkyl group, or the like; R2 represents a hydrogen atom, a lower alkyl group, a halogen atom, or the like; R3 represents a hydrogen atom, a lower alkyl group, a hydroxyl group, or a halogen atom; R4 represents a hydrogen atom or a lower alkyloxy group; R5 represents a hydrogen atom, a lower alkyloxy group, a halogen atom, a hydroxyl group, or a methylenedioxy group formed together with R6 or an isopropylidenedioxy group formed together with R6; R6 represents a hydrogen atom, a lower alkyloxy group, or a methylenedioxy group formed together with R5 or an isopropylidenedioxy group formed together with R5; R7 represents a hydrogen atom or a lower alkyl group; and R8 represents a hydrogen atom, a hydroxyl group, an amino group, a lower alkylcarbonyloxy group, or a halogen atom.
    Type: Application
    Filed: October 23, 2009
    Publication date: August 18, 2011
    Applicant: KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Takashi Ikeda, Seigo Sawada, Takashi Yaegashi, Takeshi Matsuzaki, Shusuke Hashimoto, Ryuta Yamazaki
  • Patent number: 7862908
    Abstract: The present invention discloses a conjugated compound containing a hydroindoloacridine structural element and its applications as a host material or a hole transport material in an organic electronic device. The general structure of the conjugated compound containing a hydroindoloacridine structural element is as follows: where R1˜R5 can be identical or different.
    Type: Grant
    Filed: November 26, 2007
    Date of Patent: January 4, 2011
    Assignee: National Tsing Hua University
    Inventors: Chien-Hong Cheng, Jin-Ju Lin
  • Patent number: 7847125
    Abstract: A compound having the formula: R1 and R2 together with the carbon atoms to which they are bonded are joined together to form a C3-C30 ring. The C3-C30 ring may be substituted with one or more substituents or unsubstituted. The C3-C30 ring may contain one or more heteroatoms. The C3-C30 ring may be saturated, partially unsaturated, or fully unsaturated.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: December 7, 2010
    Assignee: Chemtura Corporation
    Inventors: Qinggao Ma, Cyril Migdal
  • Publication number: 20100216773
    Abstract: Treatment of coronavirus infection with phenanthroindolizidine analogues.
    Type: Application
    Filed: February 11, 2010
    Publication date: August 26, 2010
    Applicant: National Health Research Institutes
    Inventors: Shiow-Ju Lee, Cheng-Wei Yang, Yue-Zhi Lee
  • Publication number: 20100127618
    Abstract: There is provided an organic light-emitting device having an optical output with a high efficiency, a high luminance, and a long life.
    Type: Application
    Filed: May 16, 2008
    Publication date: May 27, 2010
    Applicant: CANON KABUSHIKI KAISHA
    Inventors: Hiroki Ohrui, Akihito Saitoh, Chika Negishi, Hironobu Iwawaki, Masanori Muratsubaki, Shinjiro Okada
  • Publication number: 20100105700
    Abstract: Provided herein are inhibitors of CYP17 enzyme. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions.
    Type: Application
    Filed: October 21, 2009
    Publication date: April 29, 2010
    Applicant: LEAD THERAPEUTICS, INC.
    Inventors: Daniel Chu, Peter L. Myers, Bing Wang
  • Publication number: 20100065827
    Abstract: Disclosed are new compounds and an organic light emitting diode using the same. The organic light emitting diode using the new compound according to the present invention exhibits excellent characteristics in terms of actuating voltage, light efficiency, and lifespan.
    Type: Application
    Filed: December 3, 2007
    Publication date: March 18, 2010
    Inventors: Byung-Sun Jeon, Jeung-Gon Kim, Wook-Dong Cho, Chang-Kwan Kim, Hyun Nam
  • Publication number: 20100065828
    Abstract: Disclosed are new compounds and an organic light emitting diode using the same. The organic light emitting diode using the new compound according to the present invention exhibits excellent characteristics in terms of actuating voltage, light efficiency, and lifespan.
    Type: Application
    Filed: December 3, 2007
    Publication date: March 18, 2010
    Inventors: Byung-Sun Jeon, Wook-Dong Cho, Jeung-Gon Kim, Sang-Young Jeon, Yeon-Hwan Kim
  • Patent number: 7671068
    Abstract: Compounds of the formula I in which the substitutents have the definitions provided in the specification, are novel, effective PDE 3/4 inhibitors.
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: March 2, 2010
    Assignee: NYCOMED GmbH
    Inventor: Dieter Flockerzi
  • Patent number: 7557118
    Abstract: A method for the preparation of a compound of general Formula: or pharmaceutically acceptable derivatives and salts, racemates, isomers and/or tautomers thereof comprising cyclizing an azomethine ylide of general Formula: wherein, A is a cyclic or non-cyclic group; Z is a carbon or a heteroatom; n is selected from 0, 1, 2 or 3; W, X and Y may be the same or different and each are selected from hydrogen; optionally substituted alkyl, alkenyl, alkynyl, amino, alkoxy, alkenoxy, alkynoxy, aryl, alkylthio, heterocyclyl; carboxy, carboxy ester, carboxamido, acyl, acyloxy, mercapto, halogen, nitro, sulfate, phosphate, cyano and optionally protected hydroxy; or W and X, together with the nitrogen and carbon atoms to which they are attached, form a saturated or unsaturated nitrogen containing heterocyclic group which may be optionally substituted or optionally fused to a saturated or unsaturated carbocyclic group, aryl group or heterocyclic group is provided.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: July 7, 2009
    Assignee: The Australian National University
    Inventors: Martin Gerhardt Banwell, Bernard Luke Flynn
  • Publication number: 20090136779
    Abstract: The present invention discloses a conjugated compound containing a hydroindoloacridine structural element and its applications as a host material or a hole transport material in an organic electronic device. The general structure of the conjugated compound containing a hydroindoloacridine structural element is as follows: where R1˜R5 can be identical or different.
    Type: Application
    Filed: November 26, 2007
    Publication date: May 28, 2009
    Inventors: Chien-Hong Cheng, Jin-Ju Lin
  • Publication number: 20090131290
    Abstract: A compound having the formula: R1 and R2 together with the carbon atoms to which they are bonded are joined together to form a C3-C30 ring. The C3-C30 ring may be substituted with one or more substituents or unsubstituted. The C3-C30 ring may contain one or more heteroatoms. The C3-C30 ring may be saturated, partially unsaturated, or fully unsaturated.
    Type: Application
    Filed: November 16, 2007
    Publication date: May 21, 2009
    Inventors: Qinggao Ma, Cyril Migdal
  • Publication number: 20090121625
    Abstract: To provide a material for an organic light emitting device showing a light emission hue with an extremely good purity and outputting light having high luminance and a long lifetime with high efficiency, the present invention relates to a fused heterocyclic compound having at least one partial structure represented by the following general formula [1].
    Type: Application
    Filed: July 31, 2007
    Publication date: May 14, 2009
    Applicant: CANON KABUSHIKI KAISHA
    Inventors: Hiroki Ohrui, Shinjiro Okada, Akihiro Senoo, Naoki Yamada, Masanori Muratsubaki
  • Patent number: 7488825
    Abstract: A method for preparing a novel crystalline polymorphic irinotecan hydrochloride which is excellent in the solubility in water and reduced in the content of impurities is provided. A method for preparing c-type crystals of irinotecan hydrochloride having diffraction peaks (2?) at 9.15°, 10.00°, 11.80°, 12.20°, 13.00° and 13.40° in the powder X-ray diffractometry characterized by mixing irinotecan with one or more solvents selected from the group consisting of acetone, acetonitrile and tetrahydrofuran, adding hydrochloric acid, and collecting the formed crystals.
    Type: Grant
    Filed: February 24, 2004
    Date of Patent: February 10, 2009
    Assignee: Kabushiki Kaisha Yakult Honsha
    Inventors: Hideaki Shimizu, Atsuhiro Abe, Takashi Yaegashi, Seigo Sawada
  • Publication number: 20080234287
    Abstract: The invention discloses novel sulfur-containing naphthalimide derivatives, and the preparation and uses thereof. The conjugated plane of naphthalimide derivatives of the invention is enlarged by incorporating 5- or 6-membered heteroaromatic ring and/or introducing S heteroatom, thus increasing the anti-tumor activity of naphthalimide. The compounds of the invention displays significant inhibiting activities to the proliferation of various tumor cells such as human lung cancer, gastric cancer, liver cancer, leucocythemia and the like. The inhibition of cell proliferation is dose-dependent.
    Type: Application
    Filed: May 7, 2008
    Publication date: September 25, 2008
    Inventors: Xuhong Qian, Yonggang Li, Yufang Xu, Jian Ding, Liping Lin, Zehong Miao, Hong Zhu, Baoyuan Qu
  • Patent number: 7332502
    Abstract: A group of novel phenanthroindolizidine alkaloid compounds as shown and their use in treating cancer. Also disclosed are methods of using phenanthroindolizidine alkoid compounds in suppressing NO and TNF-? production, inhibiting MEKK1 activity and cyclooxygenase II expression, and treating NO-related disorders.
    Type: Grant
    Filed: June 13, 2005
    Date of Patent: February 19, 2008
    Assignee: National Health Research Institutes
    Inventors: Shiow-Ju Lee, Cheng-Wei Yang